Breast cancer: Zoledronic acid--more than just a bone drug

Aju Mathew; Adam Brufsky

doi:10.1038/nrclinonc.2014.152

Breast cancer: Zoledronic acid--more than just a bone drug

Nat Rev Clin Oncol. 2014 Oct;11(10):564-5. doi: 10.1038/nrclinonc.2014.152. Epub 2014 Sep 9.

Authors

Aju Mathew¹, Adam Brufsky¹

Affiliation

¹ University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Center Avenue, Pittsburgh, PA 15232, USA.

PMID: 25200411
DOI: 10.1038/nrclinonc.2014.152

Abstract

Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although negative,highlight the potential benefit of treatment with zoledronic acid in postmenopausal women with high-risk early stage breast cancer.

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Density Conservation Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / mortality*
Diphosphonates / therapeutic use*
Female
Humans
Imidazoles / therapeutic use*
Zoledronic Acid

Substances

Bone Density Conservation Agents
Diphosphonates
Imidazoles
Zoledronic Acid

Grants and funding

U10 CA180844/CA/NCI NIH HHS/United States